These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 21333719

  • 1. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.
    Neuroscience; 2011 Apr 28; 180():280-92. PubMed ID: 21333719
    [Abstract] [Full Text] [Related]

  • 2. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ.
    Exp Neurol; 2002 May 28; 175(1):35-48. PubMed ID: 12009758
    [Abstract] [Full Text] [Related]

  • 3. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein.
    Yavich L, Oksman M, Tanila H, Kerokoski P, Hiltunen M, van Groen T, Puoliväli J, Männistö PT, García-Horsman A, MacDonald E, Beyreuther K, Hartmann T, Jäkälä P.
    Neurobiol Dis; 2005 Nov 28; 20(2):303-13. PubMed ID: 16242637
    [Abstract] [Full Text] [Related]

  • 4. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.
    Acta Neuropathol Commun; 2017 Feb 01; 5(1):11. PubMed ID: 28143577
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA.
    Neurobiol Dis; 2001 Jun 01; 8(3):535-9. PubMed ID: 11442360
    [Abstract] [Full Text] [Related]

  • 7. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.
    Gaugler MN, Genc O, Bobela W, Mohanna S, Ardah MT, El-Agnaf OM, Cantoni M, Bensadoun JC, Schneggenburger R, Knott GW, Aebischer P, Schneider BL.
    Acta Neuropathol; 2012 May 01; 123(5):653-69. PubMed ID: 22361813
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T.
    Neurochem Int; 2009 Dec 01; 55(8):760-7. PubMed ID: 19647776
    [Abstract] [Full Text] [Related]

  • 9. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R, Cóppola-Segovia V, Miquel-Rio L, Alarcón-Aris D, Rodríguez-Aller R, Torres-López M, Paz V, Ruiz-Bronchal E, Campa L, Artigas F, Montefeltro A, Revilla R, Bortolozzi A.
    Int J Mol Sci; 2021 Mar 13; 22(6):. PubMed ID: 33805843
    [Abstract] [Full Text] [Related]

  • 10. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
    Unger EL, Eve DJ, Perez XA, Reichenbach DK, Xu Y, Lee MK, Andrews AM.
    Neurobiol Dis; 2006 Feb 13; 21(2):431-43. PubMed ID: 16230020
    [Abstract] [Full Text] [Related]

  • 11. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
    Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M, Nakashima M.
    Parkinsonism Relat Disord; 2009 Nov 13; 15(9):649-54. PubMed ID: 19345133
    [Abstract] [Full Text] [Related]

  • 12. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
    Jimenez-Ferrer I, Jewett M, Tontanahal A, Romero-Ramos M, Swanberg M.
    Neurobiol Dis; 2017 Oct 13; 106():279-290. PubMed ID: 28736195
    [Abstract] [Full Text] [Related]

  • 13. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P.
    Proc Natl Acad Sci U S A; 2002 Aug 06; 99(16):10813-8. PubMed ID: 12122208
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M, Mattsson B, Björklund A.
    Exp Neurol; 2012 May 06; 235(1):306-15. PubMed ID: 22394547
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M.
    J Neurosci Res; 2008 Feb 15; 86(3):640-6. PubMed ID: 17896793
    [Abstract] [Full Text] [Related]

  • 16. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
    Piltonen M, Savolainen M, Patrikainen S, Baekelandt V, Myöhänen TT, Männistö PT.
    Neuroscience; 2013 Feb 12; 231():157-68. PubMed ID: 23219665
    [Abstract] [Full Text] [Related]

  • 17. Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages.
    Nuber S, Petrasch-Parwez E, Arias-Carrión O, Koch L, Kohl Z, Schneider J, Calaminus C, Dermietzel R, Samarina A, Boy J, Nguyen HP, Teismann P, Velavan TP, Kahle PJ, von Hörsten S, Fendt M, Krüger R, Riess O.
    Neurobiol Dis; 2011 Nov 12; 44(2):192-204. PubMed ID: 21767644
    [Abstract] [Full Text] [Related]

  • 18. Methylphenidate modifies overflow and presynaptic compartmentalization of dopamine via an α-synuclein-dependent mechanism.
    Chadchankar H, Ihalainen J, Tanila H, Yavich L.
    J Pharmacol Exp Ther; 2012 May 12; 341(2):484-92. PubMed ID: 22344407
    [Abstract] [Full Text] [Related]

  • 19. Motor impairment and aberrant production of neurochemicals in human alpha-synuclein A30P+A53T transgenic mice with alpha-synuclein pathology.
    Ikeda M, Kawarabayashi T, Harigaya Y, Sasaki A, Yamada S, Matsubara E, Murakami T, Tanaka Y, Kurata T, Wuhua X, Ueda K, Kuribara H, Ikarashi Y, Nakazato Y, Okamoto K, Abe K, Shoji M.
    Brain Res; 2009 Jan 23; 1250():232-41. PubMed ID: 18992718
    [Abstract] [Full Text] [Related]

  • 20. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.
    Nieto M, Gil-Bea FJ, Dalfó E, Cuadrado M, Cabodevilla F, Sánchez B, Catena S, Sesma T, Ribé E, Ferrer I, Ramírez MJ, Gómez-Isla T.
    Neurobiol Aging; 2006 Jun 23; 27(6):848-56. PubMed ID: 16006012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.